Candida africana: Antifungal susceptibility testing of 10 clinical isolates

Introduction and Objectives: In recent years, the classification of Candida albicans has been subject to significant change, involving the description of new species such as C. dubliniensis and C. africana, which are regarded as cryptic species complexes. Epidemiological and clinical data presented to date show that C. africana has a worldwide distribution, having been isolated from vaginal specimens as well as from bloodstream, renal and systemic infections. The objective was to define the in vitro susceptibility profiles of fluconazole against 10 clinical isolates of C. africana. Materials and Methods: The in vitro antifungal susceptibility of 10 C. africana strains isolated from 128 patients with recurrent vulvovaginal candidiasis (RVVC) to fluconazole were assayed according to recommendations, stated in the Clinical and Laboratory Standards Institute (CLSI) M27-A3 and M27-S4 protocols. Results: C. africana isolates were susceptible to fluconazole and the MIC range, GM MIC, MIC50 and MIC90 were as follows; 0.063-0.25, 0.12, 0.125 and 0.25 μg/mL respectively. Conclusion: In our study, none of vaginal isolates of C. africana were fluconazole resistant.